Luminex Corp (LMNX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Luminex Corp (LMNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013941
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Luminex Corp (Luminex) is a medical devices company which develops, manufactures and markets proprietary biological testing technologies. The company offers wide range of products including instruments, assays, reagents and accessories, software and replacement parts. Its proprietary technologies consist of xMAP technology, xTAG and MultiCode technology. Luminex offers its products to various markets such as clinical diagnostics; pharmaceutical drug discovery; biomedical research including personalized medicine, genomic and proteomic research, biodefense research and food safety. The company sells its products through direct sales channel and strategic distribution partners in North America, Europe and Asia-Pacific. Luminex is headquartered in Texas, the US.

Luminex Corp (LMNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Luminex Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Luminex Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Luminex Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Luminex Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Luminex Corp, Medical Devices Deals, 2011 to YTD 2017 9
Luminex Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Luminex Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Luminex Extends Distribution Agreement With EMD Millipore 11
Equity Offering 12
Nanosphere Raises USD10 Million in Public Offering of Shares 12
Nanosphere to Raise USD4.4 Million in Private Placement of Convertible Preferred Stock 14
Nanosphere Raises USD4.4 Million in Private Placement of Series A Convertible Preferred Stock 15
Acquisition 16
Luminex Acquires Nanosphere in Tender Offer 16
Luminex Corp – Key Competitors 18
Luminex Corp – Key Employees 19
Luminex Corp – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 22
Financial Announcements 22
Oct 30, 2017: Luminex Reports Third Quarter 2017 Financial Results 22
Aug 07, 2017: Luminex Reports Second Quarter 2017 Financial Results 23
May 01, 2017: Luminex Reports Record First Quarter 2017 Financial Results; Raises 2017 Financial Guidance 24
Feb 06, 2017: Luminex Reports Fourth Quarter And Full Year 2016 Results 25
Jan 09, 2017: Luminex Announces Preliminary Revenue for Fourth Quarter 2016 and Issues 2017 Revenue Guidance 26
Oct 31, 2016: Luminex Reports Third Quarter 2016 Results; Raises Full Year Guidance 27
Jul 28, 2016: Luminex Reports Second Quarter 2016 Results 28
May 02, 2016: Luminex Reports First Quarter 2016 Results 29
Feb 01, 2016: Luminex Reports Fourth Quarter And Full Year 2015 Results 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Luminex Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Luminex Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Luminex Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Luminex Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Luminex Corp, Deals By Therapy Area, 2011 to YTD 2017 8
Luminex Corp, Medical Devices Deals, 2011 to YTD 2017 9
Luminex Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Luminex Extends Distribution Agreement With EMD Millipore 11
Nanosphere Raises USD10 Million in Public Offering of Shares 12
Nanosphere to Raise USD4.4 Million in Private Placement of Convertible Preferred Stock 14
Nanosphere Raises USD4.4 Million in Private Placement of Series A Convertible Preferred Stock 15
Luminex Acquires Nanosphere in Tender Offer 16
Luminex Corp, Key Competitors 18
Luminex Corp, Key Employees 19
Luminex Corp, Other Locations 20
Luminex Corp, Subsidiaries 20

★海外企業調査レポート[Luminex Corp (LMNX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nine Dragons Paper (Holdings) Ltd:企業の戦略・SWOT・財務情報
    Nine Dragons Paper (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary Nine Dragons Paper (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Petrol dd Ljubljana (PETG):企業の財務・戦略的SWOT分析
    Petrol dd Ljubljana (PETG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Noel Gifts International Ltd. (543):企業の財務・戦略的SWOT分析
    Noel Gifts International Ltd. (543) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • UBS Group AG:企業のM&A・事業提携・投資動向
    UBS Group AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's UBS Group AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Claris Lifesciences Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Claris Lifesciences Ltd (Claris) is a manufacturer of generic drugs and pharmaceutical products. The company provides generic drugs that are directly injected into the human body, which is mainly used in the treatment of critical illnesses. It provides products are offered through various de …
  • Sun A. Kaken Co. Ltd.:企業の戦略・SWOT・財務情報
    Sun A. Kaken Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sun A. Kaken Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • ICICI Bank Ltd:戦略・SWOT・企業財務分析
    ICICI Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary ICICI Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Protege Energy III LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Protege Energy III LLC (Protege Energy) is an oil and gas exploration and production company. The company offers acquisition and development of oil and gas reserves including exploration, development, operations, horizontal drilling, reservoir stimulations, recompletions, artificial lift and …
  • Larsen & Toubro Limited:企業の戦略・SWOT・財務情報
    Larsen & Toubro Limited - Strategy, SWOT and Corporate Finance Report Summary Larsen & Toubro Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Bank of Japan (8301):企業の財務・戦略的SWOT分析
    Bank of Japan (8301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Tocagen Inc (TOCA):製薬・医療:M&Aディール及び事業提携情報
    Summary Tocagen Inc (Tocagen) is a clinical-stage cancer-selective gene therapy company that develops and commercializes product candidates for the treatment of cancer. The company offers lead product candidate such as Toca 511 and Toca FC, which is being investigated for the treatment of recurrent …
  • CHS Inc (CHSCP):企業の財務・戦略的SWOT分析
    CHS Inc (CHSCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • genOway SA (ALGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary genOway SA (genOway) is a biotechnology company that develops genetically modified mouse, rat and cellular models for pharmaceutical companies and research institutes. The company develops several technology platforms such as safe DNA transgenesis, quick knock-in, safe in vivo RNAi and safe …
  • Sumitomo Mitsui Trust Holdings Inc
    Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Ashley Furniture Industries Inc:企業の戦略・SWOT・財務情報
    Ashley Furniture Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Ashley Furniture Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Topdanmark AS (TOP):企業の財務・戦略的SWOT分析
    Topdanmark AS (TOP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Yuhan Corp (000100):製薬・医療:M&Aディール及び事業提携情報
    Summary Yuhan Corp (Yuhan) researches, develops, manufactures and markets pharmaceutical products. The company offers API's and intermediates for antibiotic, antiviral, antifungal, anti-inflammatory, anti-diabetic, anti-HIV, anti-HCV, beta-lactase inhibitors, PEGlyated compounds and anti-histamines. …
  • gel-e Inc:医療機器:M&Aディール及び事業提携情報
    Summary gel-e Inc (gel-e), formerly Remedium Technologies Inc, is a medical device company that provides products for the treatment of acute wounds. The company provides spray foams, bandages, gels, films, and band-aids. It provides proprietary technology platform that helps develop wound treatment …
  • Tetra Tech Inc:企業の戦略・SWOT・財務分析
    Tetra Tech Inc - Strategy, SWOT and Corporate Finance Report Summary Tetra Tech Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Cascades Inc:戦略・SWOT・企業財務分析
    Cascades Inc - Strategy, SWOT and Corporate Finance Report Summary Cascades Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆